Prognostic Value of PSMB5 and Correlations with LC3II and Reactive Oxygen Species Levels in the Bone Marrow Mononuclear Cells of Bortezomib-Resistant Multiple Myeloma Patients
Proteasome inhibitors (PIs) constitute the most common type of induction treatment for multiple myeloma. Interactions between the proteasome, autophagy, and reactive oxygen species (ROS) have been shown in the past, thus emphasizing the need for a better understanding of the underlying pathophysiolo...
Saved in:
Main Authors: | Eva Plakoula, Georgios Kalampounias, Spyridon Alexis, Evgenia Verigou, Alexandra Kourakli, Kalliopi Zafeiropoulou, Argiris Symeonidis |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2025-01-01
|
Series: | Current Issues in Molecular Biology |
Subjects: | |
Online Access: | https://www.mdpi.com/1467-3045/47/1/32 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Bortezomib, thalidomide, and dexamethasone versus thalidomide and dexamethasone for response rates in multiple myeloma patients: a retrospective study
by: Juan M. Cano-Calderón, et al.
Published: (2025-01-01) -
The prognostic value of the platelet-to-lymphocyte ratio in multiple myeloma patients treated with a bortezomib-based regimen
by: Quane Zhang, et al.
Published: (2025-01-01) -
Bortezomib-releasing silica-collagen xerogels for local treatment of osteolytic bone- and minimal residual disease in multiple myeloma
by: Dirk Hose, et al.
Published: (2024-12-01) -
Guillain-Barré syndrome in patients with multiple myeloma: three cases report and literature review
by: Zhichao Li, et al.
Published: (2025-01-01) -
Real-world outcomes of maintenance therapy post-autologous stem cell transplantation in newly diagnosed multiple myeloma
by: Ka-Won Kang, et al.
Published: (2025-02-01)